← All Idexx Laboratories INC /DE filings

Idexx Laboratories INC /DE DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
IDXX
Idexx Laboratories INC /DE
DEF: IDEXX Reports Strong 2025 Growth, Announces CEO Transition
IDEXX Laboratories achieved solid 2025 financial results with 10% revenue growth and 23% diluted EPS increase, alongside a planned CEO transition and significant innovation advancements.
NASDAQ
IDXX
Idexx Laboratories INC /DE
DEFA14A: IDEXX Laboratories Files Definitive Proxy Statement
IDEXX Laboratories has filed a definitive proxy statement with the SEC.
NASDAQ
IDXX
Idexx Laboratories INC /DE
DEF 14A: IDEXX Laboratories Aims for Long-Term Growth with Innovation and Strategic Initiatives
IDEXX Laboratories reports strong financial results and advancements in its innovation-driven growth strategy, positioning the company for sustained long-term value creation.
NASDAQ
IDXX
Idexx Laboratories INC /DE
DEFA14A: IDEXX Laboratories Files Definitive Proxy Statement
IDEXX Laboratories has filed a definitive proxy statement with the SEC.
NASDAQ
IDXX
Idexx Laboratories INC /DE
DEF 14A: IDEXX Laboratories Announces Details for 2024 Annual Shareholder Meeting
IDEXX Laboratories has released its proxy statement detailing proposals for the upcoming annual shareholder meeting on May 6, 2024, including the election of directors, ratification of the accounting firm, and an advisory vote on executive compensation.